Effect of Proprietary Chinese Medicine on Coronary Microvascular Dysfunction in Patients with Microvascular Angina: A Systematic Review and Meta-Analysis

Table 5

Subgroup analysis of hs-CRP based on dosage form, drug, sample size, treatment duration, sex ratio, average age, location, and year.

Items	Subgroup	n	SMD (95% CI)	I ^2 (%)	z
Dosage form	Pill	4	−0.72 (−0.97, −0.48)	0.0	−5.712	<0.001
	Dropping pill	2	−2.49 (−5.16, 0.18)	96.9	−1.832	0.067
	Capsule	3	−1.00 (−1.92, −0.86)	90.4	−2.135	0.033
Drug	SBP	2	−0.79 (−1.16, −0.42)	6.6	−4.18	<0.001
	XKSP	2	−0.66 (−1.01, −0.32)	0.0	−3.77	<0.001
Sample size	≥80	3	−1.63 (−3.48, 0.22)	97.9	−1.729	0.084
	<80	6	−0.95 (−1.32, −0.59)	61.0	−5.111	<0.001
Treatment duration	≥6 months	4	−1.07 (−1.56, −0.57)	71.7	−4.219	<0.001
	<6 months	5	−1.29 (−2.43, −0.14)	95.9	−2.207	0.027
Sex ratio	F/M ≥ 100%	6	−1.41 (−2.42, −0.40)	95.3	−2.741	0.006
	F/M < 100%	3	−0.83 (−1.12, −0.56)	0.0	−5.911	<0.001
Average age	>60	2	−2.21 (−5.40, 0.98)	98.5	−1.358	0.175
	<60	7	−0.89 (−1.27–0.50)	74.6	−4.485	<0.001
Location	North	5	−1.26 (−2.34, −0.17)	95.9	−2.273	0.023
	South	4	−1.11 (−1.65, −0.57)	72.2	−4.038	<0.001
Year	2019	3	−0.76 (−1.03, −0.49)	0.0	−5.462	<0.001